Sarepta Therapeutics (SRPT) Income from Continuing Operations (2010 - 2026)

Sarepta Therapeutics has reported Income from Continuing Operations for 17 years, with the latest figure at -$4.9 million in Q2 2026.

• On a quarterly basis, Income from Continuing Operations fell 102.48% year-over-year to -$4.9 million in Q2 2026; TTM through Jun 2026 was -$137.1 million, a 135.65% decrease from a year earlier, with the FY2025 full-year figure at -$713.8 million, down 403.75% from the prior year.
• Income from Continuing Operations was -$4.9 million for Q2 2026 at Sarepta Therapeutics, down from $331.0 million in the prior quarter.
• The five-year high for Income from Continuing Operations was $331.0 million in Q1 2026, with the low at -$516.8 million in Q1 2023.
• Average Income from Continuing Operations over 5 years is -$77.4 million, with a median of -$32.5 million recorded in 2023.
• The largest YoY upside for Income from Continuing Operations was 2948.58% in 2025 against a maximum downside of 1339.01% in 2025.
• Over 5 years, Income from Continuing Operations stood at -$109.9 million in 2022, then jumped by 141.44% to $45.5 million in 2023, then soared by 248.8% to $158.8 million in 2024, then plunged by 278.34% to -$283.2 million in 2025, then jumped by 98.27% to -$4.9 million in 2026.
• The last three Income from Continuing Operations figures came in at -$4.9 million (Q2 2026), $331.0 million (Q1 2026), and -$283.2 million (Q4 2025), per Business Quant data.